Can inhibition of angiogenesis and stimulation of immune response be combined into a more effective antitumor therapy?

Cancer Immunology, Immunotherapy

Volumn 59, Issue 10, 2010, Pages 1449-1455

  Szala, Stanisław ^a   Mitrus, Iwona ^a   Sochanik, Aleksander ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Angiogenesis; Combined antitumor strategy; Immune surveillance; Microenvironment

Indexed keywords

ALPHA INTERFERON; ANGINEX; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANCER VACCINE; ENDOSTATIN; EPIDERMAL GROWTH FACTOR; L SELECTIN; PACLITAXEL; PAMIDRONIC ACID; PROTEIN INHIBITOR; SORAFENIB; SUNITINIB; TRANSFORMING GROWTH FACTOR BETA INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2 MONOCLONAL ANTIBODY; ZOLEDRONIC ACID;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CANCER RESISTANCE; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; STROMA CELL; TIGHT JUNCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 77955552155     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0873-6     Document Type: Review

References (71)

1. PC Nowell 1976 The clonal evolution of tumor cell populations Science 194 23 28 10.1126/science.959840 1:STN:280:DyaE283ntFWmsw%3D%3D 959840
2. LM Merlo JW Pepper BJ Reid CC Maley 2006 Cancer as an evolutionary and ecological process Nat Rev Cancer 6 924 935 10.1038/nrc2013 1:CAS:528: DC%2BD28Xht1Clsr3F 17109012 (Pubitemid 44862677)
3. A Mantovani P Allavena A Sica F Balkwill 2008 Cancer-related inflammation Nature 454 436 444 10.1038/nature07205 1:CAS:528:DC%2BD1cXovV2mtbg%3D 18650914
4. C Murdoch M Muthana SB Coffelt CE Lewis 2008 The role of myeloid cells in the promotion of tumour angiogenesis Nat Rev Cancer 8 618 631 10.1038/nrc2444 1:CAS:528:DC%2BD1cXovV2lsrY%3D 18633355
5. R Kalluri M Zeisberg 2006 Fibroblasts in cancer Nat Rev Cancer 6 392 401 10.1038/nrc1877 1:CAS:528:DC%2BD28XjslGitLw%3D 16572188
6. DJ Nolan A Ciarrocchi AS Mellick JS Jaggi K Bambino S Gupta E Heikamp MR McDevitt DA Scheinberg R Benezra V Mittal 2007 Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization Genes Dev 21 1546 1558 10.1101/gad.436307 1:CAS:528:DC%2BD2sXntlCruro%3D 17575055 (Pubitemid 46955726)
7. F Shojaei C Zhong X Wu L Yu N Ferrara 2008 Role of myeloid cells in tumor angiogenesis and growth Trends Cell Biol 18 372 378 10.1016/j.tcb.2008.06.003 1:CAS:528:DC%2BD1cXpsVCls7c%3D 18614368
8. M Hu K Polyak 2008 Microenvironmental regulation of cancer development Curr Opin Genet Dev 18 27 34 10.1016/j.gde.2007.12.006 1:CAS:528: DC%2BD1cXmsVartb8%3D 18282701 (Pubitemid 351694443)
9. P Allavena A Sica G Solinas C Porta A Mantovani 2008 The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages Crit Rev Oncol Hematol 66 1 9 10.1016/j.critrevonc.2007.07.004 17913510 (Pubitemid 351324128)
10. RD Stout SK Watkins J Suttles 2009 Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages J Leukoc Biol 86 1 5 10.1189/jlb.0209073
11. Y Luo H Zhou J Krueger C Kaplan S-H Lee C Dolman D Markowitz W Wu C Liu RA Reisfeld R Xiang 2006 Targeting tumor-associated macrophages as a novel strategy against breast cancer J Clin Invest 116 2132 2141 10.1172/JCI27648 1:CAS:528:DC%2BD28XnvF2mtrk%3D 16862213 (Pubitemid 44162322)
12. PJ Mishra PJ Mishra JW Glod D Banerjee 2009 Mesenchymal stem cells: flip side of the coin Cancer Res 69 1255 1258 10.1158/0008-5472.CAN-08-3562 1:CAS:528:DC%2BD1MXhslygu7o%3D 19208837
13. CC Hughes 2008 Endothelial-stromal interactions in angiogenesis Curr Opin Hematol 15 204 209 10.1097/MOH.0b013e3282f97dbc 18391786 (Pubitemid 351507572)
14. EM Zeisberg S Potenta L Xie M Zeisberg R Kalluri 2007 Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts Cancer Res 67 10123 10128 10.1158/0008-5472.CAN-07-3127 1:CAS:528:DC%2BD2sXht1erur7N 17974953 (Pubitemid 350070783)
15. L Hlatky P Hahnfeldt C Tsionou CN Coleman 1996 Vascular endothelial growth factor: environmental controls and effects in angiogenesis Br J Cancer 74 S151 S156 1:CAS:528:DyaK28XkvFalu7Y%3D
16. DI Gabrilovich S Nagaraj 2009 Myeloid-derived suppressor cells as regulators of the immune system Nature 9 162 174 1:CAS:528:DC%2BD1MXhsFeqsbw%3D
17. S Nagaraj D Gabrilovich 2008 Tumor escape mechanism governed by myeloid-derived suppressor cells Cancer Res 68 2561 2563 10.1158/0008-5472.CAN- 07-6229 1:CAS:528:DC%2BD1cXks1Git7s%3D 18413722 (Pubitemid 351556251)
18. CE Lewis M De Palma L Naldini 2007 Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2 Cancer Res 67 8429 8432 10.1158/0008-5472.CAN-07-1684 1:CAS:528:DC%2BD2sXhtVCit7%2FE 17875679 (Pubitemid 47437413)
19. DM Noonan A De Lerma Barbaro N Vannini L Mortara A Albini 2008 Inflammation, inflammatory cells and angiogenesis: decisions and indecisions Cancer Metastasis Rev 27 31 40 10.1007/s10555-007-9108-5 18087678
20. DM McDonald PL Choyke 2003 Imaging of angiogenesis: from microscope to clinic Nat Med 9 713 725 10.1038/nm0603-713 1:CAS:528:DC%2BD3sXktFOnurs%3D 12778170 (Pubitemid 36749220)
21. MW Dewhirst Y Cao B Moeller 2008 Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response Nat Rev Cancer 8 425 437 10.1038/nrc2397 1:CAS:528:DC%2BD1cXmt1Oksbo%3D 18500244 (Pubitemid 351744964)
22. RG Bristow RP Hill 2008 Hypoxia, DNA repair and genetic instability Nat Rev Cancer 8 180 192 10.1038/nrc2344 1:CAS:528:DC%2BD1cXitlOisrw%3D 18273037 (Pubitemid 351301853)
23. NC Denko 2008 Hypoxia, HIF1 and glucose metabolism in the solid tumour Nat Rev Cancer 8 705 713 10.1038/nrc2468 1:CAS:528:DC%2BD1cXhtVWksLfO 19143055
24. G Kroemer J Pouyssegur 2008 Tumor cell metabolism: cancer's Achilles' heel Cancer Cell 13 472 482 10.1016/j.ccr.2008.05.005 1:CAS:528: DC%2BD1cXns1yhtb0%3D 18538731 (Pubitemid 351766797)
25. MG Vander Heiden LC Cantley CB Thompson 2009 Understanding the Warburg effect: the metabolic requirements of cell proliferation Science 324 1029 1033 10.1126/science.1160809 1:CAS:528:DC%2BD1MXmtVKlsbg%3D 19460998
26. P Vaupel 2008 Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis Oncologist 13 Suppl 3 21 26 10.1634/theoncologist.13-S3-21 1:CAS:528:DC%2BD1cXotFaisbg%3D 18458121
27. K Polyak RA Weinberg 2009 Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits Nat Rev Cancer 9 265 273 10.1038/nrc2620 1:CAS:528:DC%2BD1MXis1Chtb0%3D 19262571
28. RP Hill DT Marie-Egyptienne DW Hedley 2009 Cancer stem cells, hypoxia and metastasis Semin Radiat Oncol 19 106 111 10.1016/j.semradonc.2008.12.002 19249648
29. SA Mani W Guo M-J Liao EN Eaton A Ayyanan Zhou M Brooks F Reinhard CC Zhang M Shipitsin LL Campbell K Polyak C Brisken J Yang RA Weinberg 2008 The epithelial-mesenchymal transition generates cells with properties of stem cells Cell 133 704 715 10.1016/j.cell.2008.03.027 1:CAS:528:DC%2BD1cXmsVOru7w%3D 18485877 (Pubitemid 351636299)
30. MJ Smyth GP Dunn RD Schreiber 2006 Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity Adv Immunol 90 1 50 10.1016/S0065-2776(06)90001-7 1:CAS:528:DC%2BD1cXhsVCjtbc%3D 16730260 (Pubitemid 43765795)
31. TJ Stewart SI Abrams 2008 How tumours escape mass destruction Oncogene 27 5894 5903 10.1038/onc.2008.268 1:CAS:528:DC%2BD1cXhtF2msbbJ 18836470
32. V Bronte S Mocellin 2009 Suppressive influences in the immune response to cancer J Immunother 32 1 11 10.1097/CJI.0b013e3181837276 19307988
33. AW Griffioen 2008 Anti-angiogenesis: making the tumor vulnerable to the immune system Cancer Immunol Immunother 57 1553 1558 10.1007/s00262-008-0524-3 1:CAS:528:DC%2BD1cXovFyitr8%3D 18438662
34. W Zou 2005 Immunosuppressive networks in the tumor environment and their therapeutic relevance Nat Rev Cancer 5 263 274 10.1038/nrc1586 1:CAS:528:DC%2BD2MXivVars7g%3D 15776005 (Pubitemid 40488632)
35. MB Meads RA Gatenby WS Dalton 2009 Environment-mediated drug resistance: a major contributor to minimal residual disease Nat Rev Cancer 9 665 674 10.1038/nrc2714 1:CAS:528:DC%2BD1MXhtVWhsb%2FP 19693095
36. B Bierie HL Moses 2006 TGFβ: the molecular Jekyll and Hyde of cancer Nat Rev Cancer 6 506 520 10.1038/nrc1926 1:CAS:528:DC%2BD28XmtFegsr4%3D 16794634 (Pubitemid 43980540)
37. F Balkwill 2009 Tumor necrosis factor and cancer Nat Rev Cancer 9 361 370 10.1038/nrc2628 1:CAS:528:DC%2BD1MXjvF2gtLk%3D 19343034
38. R Ueda M Fujita X Zhu K Sasaki ER Kastenhuber G Kohanbash HA McDonald J Harper S Lonning H Okada 2009 Systemic inhibition of transforming growth factor-β in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines Clin Cancer Res 15 6551 6559 10.1158/1078-0432.CCR-09-1067 1:CAS:528:DC%2BD1MXhtlCjsrnF 19861464
39. + T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-β monoclonal antibody Clin Cancer Res 15 6560 6569 10.1158/1078-0432.CCR-09-1066 1:CAS:528:DC%2BD1MXhtlCjsrbM 19861451
40. J Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 18 1182 1186
41. N Ferrara RS Kerbel 2005 Angiogenesis as a therapeutic target Nature 438 967 974 10.1038/nature04483 1:CAS:528:DC%2BD2MXhtlSksrnI 16355214 (Pubitemid 43093963)
42. P Carmeliet 2005 Angiogenesis in life, disease and medicine Nature 438 932 936 10.1038/nature04478 1:CAS:528:DC%2BD2MXhtlSksrjF 16355210 (Pubitemid 43093958)
43. RK Jain 2005 Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 58 62 10.1126/science.1104819 1:CAS:528:DC%2BD2MXnvFar 15637262 (Pubitemid 40093472)
44. RS Kerbel 2006 Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312 1171 1175 10.1126/science.1125950 1:CAS:528:DC%2BD28XkvVOiur8%3D 16728631 (Pubitemid 43801134)
45. C Folkins S Man P Xu Y Shaked DJ Hicklin RS Kerbel 2007 Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors Cancer Res 67 3560 3564 10.1158/0008-5472.CAN-06-4238 1:CAS:528:DC%2BD2sXkt1Kju70%3D 17440065 (Pubitemid 46762138)
46. HM Verheul HM Pinedo 2007 Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition Nat Rev Cancer 7 475 485 10.1038/nrc2152 1:CAS:528:DC%2BD2sXls1Kjsb4%3D 17522716 (Pubitemid 46809172)
47. G Bergers D Hanahan 2008 Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 592 603 10.1038/nrc2442 1:CAS:528:DC%2BD1cXovV2lsrk%3D 18650835
48. F Shojaei N Ferrara 2008 Refractorines to antivascular endothelial growth factor treatment: role of myeloid cells Cancer Res 68 5501 5504 10.1158/0008-5472.CAN-08-0925 1:CAS:528:DC%2BD1cXovVCgtbY%3D 18632597
49. JM Ebos CR Lee RS Kerbel 2009 Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy Clin Cancer Res 15 5020 5025 10.1158/1078-0432.CCR-09-0095 1:CAS:528: DC%2BD1MXpvFeisrg%3D 19671869
50. Y-Q Xiong H-C Sun W Zhang X-D Zhu P-Y Zhuang J-B Zhang L Wang W Wu L-X Qin Z-Y Tang 2009 Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells Clin Cancer Res 15 4838 4846 10.1158/1078-0432.CCR-08- 2780 1:CAS:528:DC%2BD1MXptl2gsLc%3D 19638466
51. M Pàez-Ribes E Allen J Hudock T Takeda H Okuyama F Viňals M Inoue G Bergers D Hanahan O Casanovas 2009 Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 220 231 10.1016/j.ccr.2009.01.027 19249680
52. JM Ebos CR Lee W Cruz-Munoz GA Bjamason JG Christensen RS Kerbel 2009 Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 232 239 10.1016/j.ccr.2009.01.021 1:CAS:528:DC%2BD1MXltFSmtbc%3D 19249681
53. C Guiducci AP Vicari S Sangaletti G Trinchieri MP Colombo 2005 Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection Cancer Res 65 3437 3446 1:CAS:528:DC%2BD2MXjt1yrtr8%3D 15833879
54. B Li AS Lalani TC Harding B Luan K Koprivnikar GH Tu R Prell MJ VanRoey AD Simmons K Jooss 2006 Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy Clin Cancer Res 12 6808 6816 10.1158/1078-0432.CCR-06-1558 1:CAS:528:DC%2BD28Xht1elsLzE 17121902 (Pubitemid 44876851)
55. EA Manning JG Ullman JM Leatherman JM Asquith TR Hansen TD Armstrong DJ Hicklin EM Jaffee LA Emens 2007 A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism Clin Cancer Res 13 3951 3959 10.1158/1078-0432.CCR-07-0374 1:CAS:528: DC%2BD2sXntFymt7s%3D 17606729 (Pubitemid 47037603)
56. R Roskoski Jr 2007 Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor Biochem Biophys Res Commun 356 323 328 10.1016/j.bbrc.2007.02.156 1:CAS:528:DC%2BD2sXjsVGisLo%3D 17367763 (Pubitemid 46452568)
57. S Kusmartsev E Eruslanov H Kübler T Tseng Y Sakai Z Su S Kaliberov A Heiser C Rosser P Dahm D Siemann J Vieweg 2008 Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma J Immunol 181 346 353 1:CAS:528:DC%2BD1cXnsVGjtbs%3D 18566400
58. T Osada G Chong R Tansik T Hong N Spector R Kumar HI Hurwitz I Dev AB Nixon HK Lyerly T Clay MA Morse 2008 The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients Cancer Immunol Immunother 57 1115 1124 10.1007/s00262-007-0441-x 1:CAS:528:DC%2BD1cXmt1OisLY%3D 18193223
59. J Wada H Suzuki R Fuchino A Yamasaki S Nagai K Yanai K Koga M Nakamura M Tanaka T Morisaki M Katano 2009 The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions Anticancer Res 29 881 888 1:CAS:528:DC%2BD1MXltlOqtrs%3D 19414323
60. C Alfaro N Suarez A Gonzalez S Solano L Erro J Dubrot A Palazon S Hervas-Stubbs A Gurpide JM Lopez-Picazo E Grande-Pulido I Melero JL Perez-Gracia 2009 Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes Br J Cancer 100 1111 1119 10.1038/sj.bjc.6604965 1:CAS:528:DC%2BD1MXktVGktro%3D 19277038
61. JS Ko AH Zea BI Rini JL Ireland P Elson P Cohen A Golshayan PA Rayman L Wood J Garcia R Dreicer R Bukowski JH Finke 2009 Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients Clin Cancer Res 15 2148 2157 10.1158/1078-0432.CCR-08-1332 1:CAS:528: DC%2BD1MXjtF2rurY%3D 19276286
62. MM Hipp N Hilf S Walter D Werth KM Brauer MP Radsak T Weinschenk H Singh-Jasuja P Brossart 2008 Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses Blood 111 5610 5620 10.1182/blood-2007-02-075945 1:CAS:528:DC%2BD1cXnsVOktLg%3D 18310500
63. J Ozao-Choy G Ma J Kao GX Wang M Meseck M Sung M Schwartz CM Divino P-Y Pan S-H Chen 2009 The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies Cancer Res 69 2514 2522 10.1158/0008-5472.CAN-08-4709 1:CAS:528:DC%2BD1MXjtFyqurY%3D 19276342
64. G Bergers R Brekken G McMahon TH Vu T Itoh K Tamaki K Tanzawa P Thorpe S Itohara Z Werb D Hanahan 2000 Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis Nat Cell Biol 2 737 744 10.1038/35036374 1:CAS:528:DC%2BD3cXnsVyntLk%3D 11025665
65. C Melani S Sangaletti FM Barazzetta Z Werb MP Colombo 2007 Amino-biphosphonate mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma Cancer Res 67 11438 11446 10.1158/0008-5472.CAN-07- 1882 1:CAS:528:DC%2BD2sXhtlyiu7rF 18056472 (Pubitemid 350248572)
66. AEMJ Dirkx MGA oude Egbrink C Castermans DWJ van der Schaft VLJL Thijssen RPM Dings L Kwee KH Mayo J Wagstaff JCA Bouma-ter Steege AW Griffioen 2006 Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors FASEB J 20 621 630 10.1096/fj.05-4493com 1:CAS:528:DC%2BD28Xjtlaqs70%3D 16581970 (Pubitemid 44933306)
67. T Kubota H Taiyoh A Matsumara Y Murayama D Ichikawa K Okamoto H Fujiwara H Ikoma M Nakanishi S Kikuchi T Ochiai C Sakakura Y Kokuba T Sonoyama Y Suzuki K Matsumoto T Nakamura E Otsuji 2009 Gene transfer of NK4, an angiogenesis inhibitor, induces CT26 tumor regression via tumor-specific T lymphocyte activation Int J Cancer 125 2879 2886 10.1002/ijc.24735 1:CAS:528: DC%2BD1MXhtlSqsLnJ 19588506
68. B Escudier A Pluzanska P Koralewski A Ravaud S Bracarda C Szczylik C Chevreau M Filipek B Melichar E Bajetta V Gorbunova J-O Bay I Bodrogi A Jagiello-Gruszfeld N Moore 2007 Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial Lancet 370 2011 2103 10.1016/S0140-6736(07)61865-0 (Pubitemid 350236338)
69. JA Gollob WK Rathmell TM Richmond CB Marino EK Miller G Grigson C Watkins L Gu BL Peterson JJ Wright 2007 Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer J Clin Oncol 25 3288 3295 10.1200/JCO.2007.10.8613 1:CAS:528: DC%2BD2sXhtVWqs7jM 17664476 (Pubitemid 47325614)
70. CW Ryan BH Goldman PN Lara Jr PC Mack TM Beer CM Tangen D Lemmon C-X Pan HA Drabkin ED Crawford 2007 Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group J Clin Oncol 25 3296 3301 10.1200/JCO.2007.11.1047 1:CAS:528:DC%2BD2sXhtVWqs7jO 17664477 (Pubitemid 47325615)
71. M Kamrava MB Bernstein K Camphausen JW Hodge 2009 Combining radiation, immunotherapy, and antiangiogenic agents in the management of cancer: the three musketeers or just another quixotic combination? Mol BioSyst 5 1262 1270 10.1039/b911313b 1:CAS:528:DC%2BD1MXht1CqsbbM 19823740